Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
Open Access
- 23 September 2021
- journal article
- research article
- Published by Springer Nature in npj Breast Cancer
- Vol. 7 (1) , 1-5
Abstract
The vast majority of studies investigating immune checkpoint inhibition (ICI) in patients with breast cancer have focused on triple-negative breast cancer (TNBC). In this study, we compared the tumor immune microenvironment (TIME) between TNBC and hormone receptor-negative HER2-positive breast cancer based on a selection of immune markers at the protein level in an institutional retrospective series. Additionally, we performed a similar comparison using publicly available transcriptomics data. Altogether, the results show a comparable TIME in both groups, with possible implications for the use of ICI in patients with hormone receptor-negative HER2-positive breast tumors.Keywords
Funding Information
- Kom Op Tegen Kanker Fonds Nadine De Beauffort Research grant from the Investigator initiated studies program of MSD to Ann Smeets
- Recipient of a post-doctoral mandate from the Klinsche Onderzoek en OpleidingsRaad (KOOR) of the University Hospitals Leuven
This publication has 24 references indexed in Scilit:
- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast CancerJAMA Oncology, 2016
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and TrastuzumabJAMA Oncology, 2015
- Robust enumeration of cell subsets from tissue expression profilesNature Methods, 2015
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialAnnals of Oncology, 2014
- Lymph node involvement in immunohistochemistry-based molecular classifications of breast cancerJournal of Surgical Research, 2013
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast CancerJournal of Clinical Oncology, 2010
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based TherapyThe Oncologist, 2006
- Estimating the Number of Clusters in a Data Set Via the Gap StatisticJournal of the Royal Statistical Society Series B: Statistical Methodology, 2001